J&J's new multiple myeloma fighter gets FDA priority review

The FDA put Johnson & Johnson's ($JNJ) new multiple myeloma treatment into the priority review lane for approval. The drug, daratumumab, is up for a green light for patients with hard-to-treat disease, or who have failed on at least two standard types of therapy. The anti-CD38 antibody could be a first-in-class treatment for the disease; the agency's decision deadline is in March 2016. Release

Suggested Articles

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

Novo Nordisk just won an FDA approval that could help it stand out in the crowded—and competitive—basal insulin category.

Pfizer is training pharmacists in the U.K. to handle over-the-counter Viagra.